Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01005290 · ClinicalTrials.gov registry record · Phase 2
A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure
A Phase 2 study, sponsored by Ferrer Internacional S.A..
- Terminated
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT01005290: Clinical Trial Phase 2 study, sponsored by Ferrer Internacional S.A..
NCT01005290 is a Phase 2 study that was terminated before completion, run by Ferrer Internacional S.A.. The registered enrollment target is 38 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01005290, a Phase 2 study, was terminated before completion, sponsored by Ferrer Internacional S.A..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effect on systolic pressure of the 3 drugs given together in the cardiovascular combination pill (acetylsalicylic acid, simvastatin, and ramipril) to the effect on systolic pressure of ramipril given alone.
Primary Outcome
Difference in the adjusted mean 24-h systolic pressure results using ABPM (Ambulatory Blood Pressure Monitoring)in the PP population.
Interventions
- DRUG Ramipril
- DRUG Combination pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Why NCT01005290 stopped before completion
NCT01005290 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 2 interventions - of which Ramipril is the first listed.
NCT01005290 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01005290 about?
NCT01005290 is a clinical study titled "A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure". The purpose of this study is to compare the effect on systolic pressure of the 3 drugs given together in the cardiovascular combination pill (acetylsalicylic acid, simvastatin, and ramipril) to the effect on systolic pressure of ramipril given alone.
What is the current status of trial NCT01005290?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2009-10. Estimated completion is 2010-10.
What interventions are being tested in trial NCT01005290?
The interventions under investigation include: Ramipril (DRUG), Combination pill (DRUG).
Who is sponsoring clinical trial NCT01005290?
This trial is sponsored by Ferrer Internacional S.A., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01005290's enrollment target sits among peer trials
38 1467th of 2000 higher than 517 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia